Clinics in Dermatology
Volume 25, Issue 6 , Pages 529-534 , November 2007

Comorbidities in psoriasis

References 

  1. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986;172:298–304
  2. Naldi L, Parazzini F, Brevi A, et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol. 1992;127:212–217
  3. Christophers E, Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res. 1987;297:48–51
  4. Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events are related to psoriasis among women. Br J Dermatol. 1994;130:473–477
  5. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:98
  6. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat. 2005;16:319–323
  7. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol. 2006;20:52–55
  8. Robinson D, Hackett M, Wong J, Kimball AB, Cohen R, Bala M The IMID Study Group. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin. 2006;22:989–1000
  9. Ho P, Bruce IN, Silman A, et al. Evidence for a common genetic control in pathways of inflammation for Crohn' diseases and psoriatic arthritis. Arthritis Rheum. 2005;52:3696–3702
  10. J.L. Alibert, Precise theorique et pratique sur les maladies de la peau. Vol. 1 Paris, Caille et Ravier, 1818, p21
  11. Finzi AF, Gibelli E. Psoriatic arthritis. Int J Dermatol. 1991;30:1–7
  12. Sege-Peterson K, Wichester R. Psoriatic arthritis. In:  Freedberg I,  Eisen AZ,  Wolff K,  Austen KF,  Goldsmith LA,  Katz SI,  Fitzpatrick TB editor. Dermatology in general medicine. 5th ed.. New York: McGraw Hill; 1999;p. 522–533
  13. Sheehan NJ. The ramifications of HLA-B27. J Roy Soc Med. 2004;97:10–14
  14. Rahman P, Schentag CT, Gladman DD. Immunogenetic profile of patients with psoriatic arthritis varies according to age at onset of psoriasis. Arthritis Rheum. 1999;42:822–823
  15. Hoffmann R, Schiefferstein G, Schunter F, et al. Increased occurrence of psoriasis in patients with Crohn's diseases and their relatives. Am J Gastroenterol. 1991;86:787–788
  16. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol. 1982;106:323–330
  17. Lee FI, Bellarys SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol. 1991;85:962–963
  18. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827–836
  19. Duerr GH, Taylor KD, Brant SR, et al. Genome-wide association study identifies IL-23R as an inflammatory bowel disease gene. Science. 2006;314:1461
  20. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β. Expert Rev Dermatol. 2007;2:69–78
  21. Mackenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23–IL-17 immune pathway. Trends Immunol. 2006;27:17
  22. Wright S, Baker H. Localized pustular psoriasis. In:  Roenigk HH,  Maibach HI editor. Psoriasis. 2nd ed.. New York: Marcel Dekker; 1991;p. 45–56
  23. von Zumbusch L. Psoriasis und pustulöses Exanthem. Arch Derm Syph Berl. 1910;99:335–346
  24. Wright S, Baker H. Generalized pustular psoriasis. In:  Edition H,  Roenigk H,  Maibach HI editor. Psoriasis. 2nd ed.. New York: Marcel Dekker; 1991;p. 109–117
  25. Zachariae H, Overgaard PH, Kissmeyer NF, Lamm L. HLA antigens in pustular psoriasis. Dermatologica. 1977;154:73–77
  26. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627–632
  27. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99:469–475
  28. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not outpatients. Eur J Epidemiol. 2004;19:225–230
  29. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321–328
  30. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480
  31. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2006;28:
  32. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303:33–39
  33. Mallbris L, Granath F, Hamsten A, Stähle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614–621
  34. Sattar N, McInnes I. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005;17:286–292
  35. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin resistance and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4:R5
  36. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how high grade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–2968
  37. Wallenberg-Jonsson S, Johansson H, Öhman ML, Rantapää-Dahlquist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562–2571
  38. Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005;32:435–442
  39. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther. 2005;7:634–643
  40. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–1177
  41. Ho P, Bruce IN, Symmons D, et al. Anti–tumor necrosis factor–alpha treatment improves endothelial function inpatients with rheumatoid arthritis. Circulation. 2002;106:2184–2187
  42. Jacobson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213–1218
  43. De Gannes GC, Goreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223
  44. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;178:2229
  45. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid dendritic cells initiate psoriasis through interferon-α production. J Exp Med. 2005;202:23–44

PII: S0738-081X(07)00150-2

doi: 10.1016/j.clindermatol.2007.08.006

Clinics in Dermatology
Volume 25, Issue 6 , Pages 529-534 , November 2007

Article Tools

* Image Usage & Resolution